Non-Sponsored
Advertisement
The FDA has accepted a Supplemental New Drug Application for decitabine and cedazuridine plus venetoclax for AML.
The award recognizes achievements in the field of gene and cell therapies, cellular engineering, and related disciplines.
Hematology/oncology fellow Joseph Van Galen, MD, is investigating the mechanisms behind immune-related adverse events.
Guest contributor Moaath Mustafa Ali, MD, MPH, outlines the transforming treatment paradigm of Ph+ ALL.
The study investigated the role of multi-cancer early detection tests (MCEDs) on patient survival outcomes.
Guest contributor Charles Gaulin, MBBS, outlines important updates on the first-line treatment of TP53-mutated MCL.
Advertisement
Gaps in coordination and collaboration between primary care and oncology may impact long-term survival outcomes for patients.
Linvoseltamab earns FDA nod for RRMM with 70% ORR, monthly dosing, and lower CRS than other bispecifics.
Ruxolitinib shows durable benefit and long-term safety in steroid-refractory chronic GVHD, REACH3 finds.
The model estimates patients' 2-year progression-free survival using patient information routinely recorded in the clinic.
SGR-1505 has shown promising efficacy and safety in an ongoing, phase 1 dose-escalation study.
No new safety signals were observed in this phase 3 trial which compared the combination with placebo plus azacitidine.
Revumenib has received FDA Priority Review with a Prescription Drug User Fee Act target action date of October 25, 2025.
Pirtobrutinib, CAR T, and bispecifics are reshaping CLL care for high-risk, relapsed patients with limited options.
FDA approves tafasitamab plus R2 for relapsed FL, showing 57% reduced risk of progression in phase 3 inMIND trial.
TAG shows promise as frontline therapy in BPDCN, minimizing toxicity and supporting safer stem cell transplant.
The approval of tafasitamab-cxix in combination with rituximab and lenalidomide was based on the phase 3 inMIND trial.
SENTI-202, a first-in-class, off-the-shelf, logic-gated CAR-NK cell therapy, is currently being evaluated in a phase 1 trial.
Blood Cancers Today editors Krina Patel and Rahul Banerjee reflect on paradigm-shifting myeloma research from ASCO.
Vinayak (Vinay) Prasad, MD, MPH, has been appointed director of the FDA Center for Biologic Evaluation and Research.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.